Exact Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Exact Sciences's estimated annual revenue is currently $454.5M per year.
- Exact Sciences received $747.5M in venture funding in March 2019.
- Exact Sciences's estimated revenue per employee is $56,252
- Exact Sciences's total funding is $1B.
Employee Data
- Exact Sciences has 8079 Employees.
- Exact Sciences grew their employee count by 6% last year.
Exact Sciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP and Chief Medical Officer for Multi-Cancer Early Detection | Reveal Email/Phone |
3 | VP, Chief Compliance Officer | Reveal Email/Phone |
4 | Owner Amada Senior Care Garland | Reveal Email/Phone |
5 | Integrated Evidence Plan Director, Chief Medical Affairs Office - RWE Platform | Reveal Email/Phone |
6 | Chief Information Officer | Reveal Email/Phone |
7 | Owner | Reveal Email/Phone |
8 | Chief Privacy Officer | Reveal Email/Phone |
9 | Chief Compliance Counsel | Reveal Email/Phone |
10 | Chief Member | Reveal Email/Phone |
Exact Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $434.8M | 2275 | -14% | $2B | $2.7B |
#2 | $4280M | 13590 | -4% | $28M | $63.3B |
#3 | $343.9M | 3875 | 7% | $550M | $7.9B |
#4 | $348.9M | 1407 | -18% | $2B | $2.5B |
What Is Exact Sciences?
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook. For more information on Exact Sciences' noninvasive colon cancer screening test, visit CologuardTest.com
keywords:Biotechnology,Healthcare,Human Resources Hr,Medical Diagnostics,Pharmaceuticals
$1B
Total Funding
8079
Number of Employees
$454.5M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Exact Sciences News
Brokerages Anticipate Exact Sciences Co. (NASDAQ:EXAS) Will Announce Quarterly Sales of $461.86 Million. Posted by admin on Apr 23rd, 2022.
NEW YORK Exact Sciences and Guardant Health, two major players aiming for a share of the anticipated blood-based cancer screening market,...
MADISON, Wis., April 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced...
Exact Sciences Hosts Maydm Interns This summer, Exact Sciences worked with Maydm, a community partner,to host four interns interested in science, technology, engineering and math (STEM) fields. The internship program organized by Maydm gives high school students the opportunity to utilize previ ...
Other Companies in Madison
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1708.4M | 8135 | 3% | N/A |
#2 | $2117.2M | 10082 | 2% | N/A |
#3 | $2376.4M | 11316 | 30% | N/A |
#4 | $1967.7M | 14055 | -6% | N/A |
#5 | $8128.7M | 26392 | 4% | N/A |
Exact Sciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-08-18 | $15.0M | Milestone Funding | Article | |
| 2009-06-12 | $8.2M | Undisclosed | Article | |
| 2015-07-27 | $174.0M | Undisclosed | Jefferies | Article |
| 2016-07-29 | $15.2M | Undisclosed | Jefferies LLC | Article |
| 2017-06-08 | $281.8M | Undisclosed | Jefferies LLC | Article |
| 2018-01-12 | $500.0M | Undisclosed | BofA Merrill Lynch | Article |
| 2019-03-07 | $747.5M | Undisclosed | BofA Merrill Lynch | Article |